General
Preferred name
REGADENOSON
Synonyms
CVT-3146 ()
Lexiscan ()
REGADENOSON ANHYDROUS ()
CVT-3146, Lexiscan ()
Regadenoson monohydrate ()
Rapiscan ()
Regadenoson hydrate ()
P&D ID
PD009316
CAS
313348-27-5
875148-45-1
Tags
natural product
drug
available
Approved by
FDA
First approval
2008
Drug Status
investigational
approved
Drug indication
Radionuclide imaging
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Regadenoson is a selective adenosine A2A receptor agonist, with a substantially longer biological half-life than .
(GtoPdb)
TOXICITY
The most common (incidence ⥠5%) adverse reactions to regadenoson are dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, and nausea. ; MTD (male, supine position): 20 µg/kg; ; MTD (male, standing position): 10 µg/kg;
HALF-LIFE
Initial phase: 2-4 minutes;; Intermediate phase: 30 minutes (this phase coincides with a loss of the pharmacodynamic effect); ; Terminal phase: 2 hours
ABSORPTION
The pharmacokinetic profile of regadenoson is best described by a 3-compartment model. ; T max, injection = 1 to 3 minutes;; Onset of pharmacodynamic response = 1 to 3 minutes; ; E max 12.3 ng/mL ;
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
21
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
40
Molecular Weight
390.14
Hydrogen Bond Acceptors
12
Hydrogen Bond Donors
5
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
3
cLogP
-2.43
TPSA
186.46
Fraction CSP3
0.4
Chiral centers
4.0
Largest ring
6.0
QED
0.32
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Target
A2A
ADORA1, ADORA2A, ADORA2B, ADORA3
Adenosine Receptor
Indication
myocardial perfusion imaging (MPI)
MOA
Adenosine Receptor agonist
Source data
